These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25800719)

  • 1. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY; Srivastava A; Park K; Kim J; Lee MH; Do I; Lee J; Kim KM; Sohn TS; Kang WK; Kim S
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of HER2 amplification and overexpression in early onset gastric cancer.
    Moelans CB; Milne AN; Morsink FH; Offerhaus GJ; van Diest PJ
    Cell Oncol (Dordr); 2011 Apr; 34(2):89-95. PubMed ID: 21394646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
    Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
    Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of HER2 gene amplification and protein expression in gastric cancer.
    Yan B; Yau EX; Bte Omar SS; Ong CW; Pang B; Yeoh KG; Salto-Tellez M
    J Clin Pathol; 2010 Sep; 63(9):839-42. PubMed ID: 20696687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
    van der Vegt B; de Bock GH; Bart J; Zwartjes NG; Wesseling J
    Mod Pathol; 2009 Jul; 22(7):879-86. PubMed ID: 19305385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.